Beyond Therapies
Tap into our comprehensive expertise across diverse therapy areas. We specialize in conducting research for both clinically complex and specialist indication areas, as well as general, primary care indications.
Our top therapy areas to work in are:
Navigate the complexities of oncology with strategic insight.
Oncology is fast-moving, competitive, and increasingly complex. There’s always something new - from novel modalities that bring fresh practical and logistical considerations, to evolving biomarkers that redefine how patients are selected and treated.
At the same time, as brands stretch across indications, messaging and positioning need to work in harmony across the full portfolio. All of this makes it essential to work with a partner who can see, and make sense of, the full landscape.
Stay ahead in the dynamic oncology landscape with deep scientific understanding, sharp awareness of market dynamics, technical fluency across stakeholder groups, and industry-leading moderation. This combination allows us to get to the heart of the challenge and deliver insights that drive confident decision-making.
Navigating 2024’s Oncology Hot Topics
As we embark on a new year, our oncology team has been busy crafting predictions to guide us through 2024. Continue reading to discover the key trends and game-changers our team have selected. Will it be a green light for CAR-T ambitions, or a U-turn? Stepping into...
Top takeouts from ESMO 2023
Last week, our Research Directors, Siobhan Davies and Lindsay Widger, landed back in the UK from the ESMO Congress 2023 in Madrid. The conference brought together likeminded passionate professionals in oncology to discuss and digest the very latest developments. ESMO...
ESMO Congress Madrid 2023: What’s in store?
ESMO 2023 Madrid beckons, in just over a week (20th -24th October). Our Research Directors, Lindsay Widger and Siobhan Davies, will be in attendance reporting back on the hottest topics and connecting with like-minded oncology experts to discuss the implications as...
ASCO 2023: Our key themes
A few weeks ago, we attended the ASCO Annual Meeting which brought the latest oncology developments. The meeting provides an exceptional opportunity to connect with one of the largest, most diverse audiences in global cancer care and we were extremely proud to be a...
Neoadjuvant Chemo-IO – a new standard for resectable NSCLC?
12 months ago, at ESMO 2021, the oncology community was asked, “Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?”. At that time, 71% felt the available efficacy data was not sufficient to implement...
Expert insights into future opportunities in immuno-oncology
It is widely accepted that the use of immunotherapy agents has been one of the major advances in oncology over recent years. But what further changes can we expect as the area develops in the next few years, and what does that mean for pharma? To look further into...
Oncology Trends, Views and Perspectives from Beyond Blue
What are the leading oncology issues and drug development trends, outside of reimbursement/drug access? What is the impact of COVID–19 across oncology? How can we use market research methods to maximise stakeholder insights on future oncology drug development,...
Clear thinking for complex neurology challenges
Neurology is often defined by complex, progressive conditions where the goal is not cure, but slowing decline. This creates commercialization challenges rooted in contradiction: the value of disease modification lies in early intervention, and yet at this stage symptoms may be subtle, intermittent, or management appears straightforward.
The unmet need suggests that any slowing of decline should be meaningful, and yet when benefits are hard to see, building conviction among HCPs, families, and systems becomes a challenge.
At Beyond Blue, we understand the tension between evolving science and human behavior. Complex journeys, human decisions, evolving science — these lie at the heart of commercializing neurology.
Explore how patients, caregivers, and clinicians perceive risk, progression, and value, and uncover what it takes to shift behavior when benefits aren’t immediately visible, and how to build belief in disease-modifying therapies early, when they matter most.
See our latest thinking for more insights!
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Cutting through CVRM complexity to drive impact
CVRM is becoming increasingly interconnected. Patients often live with obesity, diabetes, chronic kidney disease and cardiovascular disease simultaneously, creating more complex care pathways that span multiple specialties and healthcare settings.
The traditional physician–patient dynamic is evolving, with treatment decisions increasingly shaped by multidisciplinary teams, pharmacists, nurses and other healthcare professionals, while more informed and activated patients are playing a greater role in driving conversations and influencing care.
Navigating this complexity requires an understanding of more than the evidence. It requires insight into how value is perceived by different stakeholders, how decisions are made across the care pathway, and how healthcare system dynamics shape access, adoption and long-term success.
Stay ahead in this dynamic space with deep scientific and clinical understanding and a clear view of how care is delivered in practice. By connecting insights across diseases, stakeholders and portfolios, we help clients make sense of complexity and support confident, informed decision-making.
See our latest thinking for more insights!
Navigate the complexities of oncology with strategic insight.
Oncology is fast-moving, competitive, and increasingly complex. There’s always something new - from novel modalities that bring fresh practical and logistical considerations, to evolving biomarkers that redefine how patients are selected and treated.
At the same time, as brands stretch across indications, messaging and positioning need to work in harmony across the full portfolio. All of this makes it essential to work with a partner who can see, and make sense of, the full landscape.
Stay ahead in the dynamic oncology landscape with deep scientific understanding, sharp awareness of market dynamics, technical fluency across stakeholder groups, and industry-leading moderation. This combination allows us to get to the heart of the challenge and deliver insights that drive confident decision-making.
Check out our deep dive case study click below.
Lung Cancer Awareness Month 2024
It’s Lung Cancer Awareness Month, which made us reflect on our recent interactions with patients …. Understanding the Journey of NSCLC Patients: A Call to Action In our extensive work with non-small cell lung cancer (NSCLC), we’ve learned one undeniable truth: there...
Elevating Excellence: Expanding Our Oncology Team
Oncology has always been a key area of focus for us. As the demand for our oncology expertise continues to surge, we are thrilled to announce the expansion of our devoted team. Within the fabric of our expanding team, a key objective is to establish a dedicated group...
Navigating 2024’s Oncology Hot Topics
As we embark on a new year, our oncology team has been busy crafting predictions to guide us through 2024. Continue reading to discover the key trends and game-changers our team have selected. Will it be a green light for CAR-T ambitions, or a U-turn? Stepping into...
Top takeouts from ESMO 2023
Last week, our Research Directors, Siobhan Davies and Lindsay Widger, landed back in the UK from the ESMO Congress 2023 in Madrid. The conference brought together likeminded passionate professionals in oncology to discuss and digest the very latest developments. ESMO...
ESMO Congress Madrid 2023: What’s in store?
ESMO 2023 Madrid beckons, in just over a week (20th -24th October). Our Research Directors, Lindsay Widger and Siobhan Davies, will be in attendance reporting back on the hottest topics and connecting with like-minded oncology experts to discuss the implications as...
ASCO 2023: Our key themes
A few weeks ago, we attended the ASCO Annual Meeting which brought the latest oncology developments. The meeting provides an exceptional opportunity to connect with one of the largest, most diverse audiences in global cancer care and we were extremely proud to be a...
Neoadjuvant Chemo-IO – a new standard for resectable NSCLC?
12 months ago, at ESMO 2021, the oncology community was asked, “Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?”. At that time, 71% felt the available efficacy data was not sufficient to implement...
Expert insights into future opportunities in immuno-oncology
It is widely accepted that the use of immunotherapy agents has been one of the major advances in oncology over recent years. But what further changes can we expect as the area develops in the next few years, and what does that mean for pharma? To look further into...
Oncology Trends, Views and Perspectives from Beyond Blue
What are the leading oncology issues and drug development trends, outside of reimbursement/drug access? What is the impact of COVID–19 across oncology? How can we use market research methods to maximise stakeholder insights on future oncology drug development,...
Clear thinking for complex neurology challenges
Neurology is often defined by complex, progressive conditions where the goal is not cure, but slowing decline. This creates commercialization challenges rooted in contradiction: the value of disease modification lies in early intervention, and yet at this stage symptoms may be subtle, intermittent, or management appears straightforward.
The unmet need suggests that any slowing of decline should be meaningful, and yet when benefits are hard to see, building conviction among HCPs, families, and systems becomes a challenge.
At Beyond Blue, we understand the tension between evolving science and human behavior. Complex journeys, human decisions, evolving science — these lie at the heart of commercializing neurology.
Explore how patients, caregivers, and clinicians perceive risk, progression, and value, and uncover what it takes to shift behavior when benefits aren’t immediately visible, and how to build belief in disease-modifying therapies early, when they matter most.
See our latest thinking for more insights!
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Cutting through CVRM complexity to drive impact
CVRM is becoming increasingly interconnected. Patients often live with obesity, diabetes, chronic kidney disease and cardiovascular disease simultaneously, creating more complex care pathways that span multiple specialties and healthcare settings.
The traditional physician–patient dynamic is evolving, with treatment decisions increasingly shaped by multidisciplinary teams, pharmacists, nurses and other healthcare professionals, while more informed and activated patients are playing a greater role in driving conversations and influencing care.
Navigating this complexity requires an understanding of more than the evidence. It requires insight into how value is perceived by different stakeholders, how decisions are made across the care pathway, and how healthcare system dynamics shape access, adoption and long-term success.
Stay ahead in this dynamic space with deep scientific and clinical understanding and a clear view of how care is delivered in practice. By connecting insights across diseases, stakeholders and portfolios, we help clients make sense of complexity and support confident, informed decision-making.